Molecular Partners AG(US:MOLN)2025-10-30 20:00Financial Performance - Total revenues for the nine months ended September 30, 2025, were CHF 0, a decrease from CHF 4.97 million in the same period of 2024[11] - Operating expenses for the nine months ended September 30, 2025, were CHF 45.5 million, down 11.5% from CHF 51.4 million in 2024[11] - The net result attributable to shareholders for the nine months ended September 30, 2025, was a loss of CHF 49.0 million, compared to a loss of CHF 42.8 million in 2024[12] - The company reported a basic and diluted net result per share of CHF (1.32) for the nine months ended September 30, 2025, compared to CHF (1.29) in 2024[12] - The Group reported a net foreign exchange loss of TCHF 4,767 for the nine months ended September 30, 2025, compared to no loss in the previous year[35] Cash and Assets - Cash and cash equivalents increased to CHF 82.4 million as of September 30, 2025, from CHF 63.9 million at the beginning of the year[14] - Total assets decreased to CHF 112.2 million as of September 30, 2025, from CHF 158.5 million at the end of 2024[10] - Shareholders' equity as of September 30, 2025, was CHF 95.5 million, down from CHF 141.6 million at the end of 2024[10] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were CHF 30.9 million, a decrease of 18.5% from CHF 38.1 million in 2024[11] - The company has not reported any revenues from research and development collaborations for the third quarter of 2025, compared to CHF 681,000 in the same quarter of 2024[13] - The Group recognized no revenue from the License and Collaboration Agreement with Novartis during the three and nine months ended September 30, 2025, compared to TCHF 681 and TCHF 4,970 for the same periods in 2024, respectively[25] Shareholder Information - As of September 30, 2025, the outstanding issued share capital increased to CHF 4,037,464, divided into 40,374,641 fully paid registered shares, including 2,975,489 treasury shares[29] - The weighted average number of shares used in computing earnings per share for the nine months ended September 30, 2025, was 37,223,971, compared to 33,082,140 for the same period in 2024[37] Expenses and Restructuring - The company incurred restructuring expenses of CHF 2.7 million during the nine months ended September 30, 2025[11] - The Group recognized TCHF 2,733 as a restructuring expense for the nine months ended September 30, 2025, primarily related to personnel costs[41] - The share-based compensation costs for the nine months ended September 30, 2025, amounted to TCHF 3,446, an increase from TCHF 3,045 for the same period in 2024[34] Tax and Related Party Transactions - The Group has a tax loss carry-forward in Switzerland of TCHF 195,126 as of December 31, 2024, with no deferred tax assets recognized due to the improbability of utilizing these losses[36] - No related party transactions occurred during the interim periods presented[39] - No significant events occurred between the balance sheet date and the approval date of the financial statements that would require adjustments[42]